Akanda Corp. (AKAN)

CIK 0001888014 · Healthcare · Drug Manufacturers

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest FY-2025 —
FY-2024 —
FY-2023 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
—
Document and Entity Information
—
Audit Information
—
Statements
Consolidated Statements of Financial Position
—
Consolidated Statements of Loss and Comprehensive Loss
—
Consolidated Statements of Loss and Comprehensive Loss (P)
—
Consolidated Statements of Shareholders Equity
—
Consolidated Statements of Shareholders' Equity (deficit)
—
Consolidated Statements of Shareholders Equity (P)
—
Consolidated Statements of Shareholders' Equity (deficit) (P)
—
Consolidated Statements of Cash Flows
—
Notes
Basis of Preparation
—
Business Combination
—
Capital Management
—
Contingencies
—
Convertible Promissory Notes
—
Cybersecurity Risk Management and Strategy Disclosure
—
Financial Instruments
—
General and Administrative Expenses
—
Income Taxes
—
Insider Trading Policies and Procedures
—
Insolvency Proceedings
—
Intangible Assets
—
Intangible Assets and Goodwill
—
Inventory
—
Lease Liability
—
Loan Receivable
—
Loans and Borrowings
—
Loss of Control of Bophelo Bio Science and Wellness (pty) Ltd
—
Loss of Control of Canmart Ltd
—
Marketable Securities
—
Material Accounting Policies
—
Nature of Operations and Going Concern
—
Non-controlling Interest
—
Prepayments
—
Property, Plant and Equipment
—
Related Party Transactions
—
Revenue and Geographic Information
—
Right-of-use Assets
—
Risks Arising From Financial Instruments and Risk Management
—
Sale of Rpk
—
Segmented Information
—
Share Capital
—
Subsequent Events
—
Trade and Other Receivables
—